Abstract IA023: Improved sensitivity of a multi-analyte early detection test based on mutation, methylation, aneuploidy, and protein biomarkers (2023)

Abstract Background: A multi-analyte blood test has the potential to maximize performance for early detection across different cancer stages and types. Improvements in early-stage cancer detection might be achieved using multi-component tests with high sensitivities and specificities. We recently performed a large feasibility study to assess the performance of 4 biomarkers (aneuploidy, methylation, mutation, and protein) for the detection of cancers from up to 15 organ sites. Specifically, a training and validation set was tested for 3 biomarkers (aneuploidy, methylation, and protein) and the performance was subsequently confirmed in an independent testing set. Methods: We have now further improved the performance of a 4-marker cancer detection blood test by fine-tuning the respective marker calling models and thresholds, exploring prostate-specific antigen (PSA) for prostate cancer detection, and developing an overarching Machine Learning (ML) cancer classifier. To improve the mutation detection, we tested (in triplicate) 200 plasma and buffy samples from young, non-cancer subjects and mutant DNA from cell lines to develop an ML-based mutation calling algorithm. This caller was validated on 186 samples and tested on an independent set of 1388 cancer and non-cancer samples. The calling of cancer-associated DNA methylation events was refined by performing training, validation, and testing across different studies. We also explored models for methylation detection based solely on distribution of methylation signal observed in non-cancer samples. Free and total PSA were investigated as markers for prostate cancer detection by including clinically relevant Gleason scores in the development of the protein-based cancer calling algorithm. Results: In the previous analysis the combination of mutation, aneuploidy, methylation, and protein biomarkers resulted in an overall sensitivity of 61.0% (95% CI: 56.9%-65.0) at a specificity of 98.2% (95% CI: 97.1 – 99.4%). We will present the added performance benefit of ML-based mutation variant calling. PSA derived features were evaluated with the goal of increasing the detectability of high-grade prostate cancers while minimizing the detection of indolent cancers. Lastly, we compared the Boolean logic-based 4-biomarker combination algorithm used in the previous analysis with an ML-based cancer classifier. The results of the modeling, applied to the testing set, will be shared. Conclusions: In summary, improvements in cancer detection performance may be achieved by optimizing each biomarker calling algorithm as well as overarching cancer classifier. When combining these improvements, we believe that a single blood test will provide robust sensitivity for the detection of several cancer types, particularly for earlier-stage disease in real world settings. Citation Format: Vladimir Gianullin, Leonardo Hagmann, Kevin Arvai, Amira Djebbari, Christopher L. Nobles, Larson Hogstrom, Mael Manesse, Vuna Fa, Fanglei Zhuang, Xi Chen, Viatcheslav E. Katerov, Jorge Garces, Hatim T. Allawi, Abigail McElhinny, Frank Diehl, Gustavo C Cerqueira. Improved sensitivity of a multi-analyte early detection test based on mutation, methylation, aneuploidy, and protein biomarkers. [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): Abstract nr IA023.